Xcout Intel
Nuclidium AG competitors & alternatives
The 12 closest competitors and alternatives to Nuclidium AG among biotechnology companies — ranked by similarity to what Nuclidium AG actually does, not by market-cap band.
Subscribe to see Nuclidium AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Nuclidium AG
Nuclidium is a precision oncology company headquartered in Basel, Switzerland. It specializes in developing next-generation copper radiotheranostics to provide personalized treatment options for cancer patients at various stages.
Nuclidium AG at a glance
Nuclidium AG is a biotechnology company headquartered in Switzerland. It has raised at least $119.9M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $30.9M in May 2026. Xcout tracks 22 named people at Nuclidium AG, including Max Azaham (Chief Financial Officer).
Nuclidium AG leadership
- Max AzahamChief Financial Officer
- Dr. Thomas ReinerChief Scientific Officer
- Dr. Leila Jaafar-ThielChief Executive Officer
- Leila JaafarCEO and Co-Founder
- Prof. Dr. Gustav von Schulthess (MD, PhD)Medical Advisor & Co-Founder
- Denise LeeVP Clinical Operations
16 more named people on record for Nuclidium AG, with roles, board committees and tenure — see the full roster →
Nuclidium AG funding rounds
At least $119.9M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $30.9M | 10 named | |
| Series B | $89M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Nuclidium AG competitors
Ranked by semantic similarity — how close each company is to Nuclidium AG by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Alpha-9 Oncology Inc. is a clinical-stage radiotherapeutic company developing targeted, next-generation radiopharmaceuticals for cancer therapy with operations spanning Boston, Massachusetts and Vancouver, Canada.
Biotech
Ratio Therapeutics is a clinical-stage pharmaceutical company headquartered in Boston, Massachusetts. The company employs a suite of innovative technologies for the discovery and early clinical development of targeted radiopharmaceuticals.
Similar biotechnology company
Actithera, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on delivering targeted radioligand cancer therapies.
Similar biotechnology company
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Biotech
ARTBIO is a biotechnology company developing targeted alpha-particle radioligand therapies for cancer, including treatments intended to selectively deliver radioactive payloads to tumor cells. Its work is aimed at serving oncology patients and healthcare providers treating solid tumors.
Similar biotechnology company
Precirix is a clinical-stage biotechnology company dedicated to improving outcomes by developing precision radiopharmaceuticals for cancer therapy. Operating within the biotechnology research sector, the Brussels-based firm launched products such as CAM-FAP-Ga.
Similar biotechnology company
ITM Isotope Technologies Munich SE is a radiopharmaceutical biotech company based in Garching bei München, Germany. It develops, produces, and globally supplies targeted radiotherapeutic and diagnostic agents for cancer treatment. The company notably secured a major €255 million investment round to further advance its clinical pipeline.
Similar biotechnology company
Full-Life Technologies Limited is a fully integrated global radiopharmaceutical company focused on drug development in oncology, headquartered in Shanghai, China, with additional operations in Europe.
Biotech
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Biotech
FoRx Therapeutics is a privately held clinical-stage biotechnology company headquartered in Basel, Switzerland. The company pioneers precision therapeutics targeting DNA Replication Stress in cancer treatment. Its office is located at Lichtstrasse 35, 4056 Basel, Switzerland.
Biotech
Mariana Oncology is a fully integrated radiopharmaceutical company headquartered in Watertown, Massachusetts, that develops precision radioligand therapies to transform cancer treatment.
Biotech
Nouscom is a private, clinical-stage oncology company headquartered in Basel, Switzerland, with additional research facilities in Rome, Italy. The firm is dedicated to re-defining cancer immunotherapy through its proprietary viral vector platform.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Nuclidium AG and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Nuclidium AGand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →